Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Progenics Pharma has received $4,143,652 grant from the National Institutes of Health (NIH) for the development of new monoclonal antibodies to treat Clostridium difficile (C difficile) infection.
Subscribe to our email newsletter
Progenics’ monoclonal antibodies constitute a non-antibiotic treatment strategy that is designed to block the harmful effects of the disease-causing toxins produced by C difficile.
Progenics Pharma founder, CEO chief science officer said that they were honored to receive this competitive NIH award and were gratified that NIH elected to support their program based on its scientific merit and therapeutic potential.
Progenics’ humanised monoclonal antibodies are designed to block the cytotoxic effects of C difficile toxins and enable the normal bacteria in the colon to become reestablished.
Progenics claimed that in laboratory studies, the humanised monoclonal antibodies neutralised the cell-killing activities of the toxins produced by both conventional and hypervirulent strains of C difficile.